Calicheamicin / 1 mg

Calicheamicin is a highly potent natural product antibiotic isolated from the bacterium Micromonospora echinospora var. calichensis. It exhibits exceptional cytotoxicity against a wide range of human cancer cell lines, making it a subject of interest for cancer research and potential therapeutic development. Despite its promising activity, the use of calicheamicin in medicine is limited by its extreme potency and potential for causing severe toxic effects. Research focuses on developing less toxic analogs or delivery systems to harness its powerful anticancer properties safely.

Application

Currently, calicheamicin is not used clinically due to its high toxicity. However, it remains a critical reference compound in cancer research, providing insights into the mechanisms of action of DNA-damaging agents. Scientists study calicheamicin to understand how its potent cytotoxicity can be leveraged in cancer treatments, potentially through the development of safer derivatives or improved delivery methods.

Articles:

- An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker

Publication Date: December 19, 2001

Philip R. Hamann, Lois M. Hinman, Carl F. Beyer, Delores Lindh, Janis Upeslacis, David A. Flowers, and Irwin Bernstein

https://doi.org/10.1021/bc0100206

- Understanding and Exploiting Natures Chemical Arsenal: The Past,Present and Future of Calicheamicin Research

Publication Date: 2000

Jon S. Thorson, Eric L. Sievers, Joachim Ahlert, Erica Shepard, Ross E. Whitwam, Kenolisa C. Onwueme and Mark Ruppen

http://dx.doi.org/10.2174/1381612003398564

- The Calicheamicin Gene Cluster and Its Iterative Type I Enediyne PKS

Publication Date: 16 Aug 2002

JOACHIM AHLERT, ERICA SHEPARD, NATALIA LOMOVSKAYA, EMMANUEL ZAZOPOULOS, ALFREDO STAFFA, BRIAN O. BACHMANN, KEXUE HUANG, LEONID FONSTEIN, ANNE CZISNY, ROSS E. WHITWAM, CHRIS M. FARNET AND JON S. THORSON

https://doi.org/10.1126/science.1072105